AR049998A1 - BENZOTIAZOLES SUSTITUIDOS COMO LIGANDOS DEL RECEPTOR DE ADENOSINA, PROCESO DE PREPARACIoN Y SU USO - Google Patents
BENZOTIAZOLES SUSTITUIDOS COMO LIGANDOS DEL RECEPTOR DE ADENOSINA, PROCESO DE PREPARACIoN Y SU USOInfo
- Publication number
- AR049998A1 AR049998A1 ARP050102987A ARP050102987A AR049998A1 AR 049998 A1 AR049998 A1 AR 049998A1 AR P050102987 A ARP050102987 A AR P050102987A AR P050102987 A ARP050102987 A AR P050102987A AR 049998 A1 AR049998 A1 AR 049998A1
- Authority
- AR
- Argentina
- Prior art keywords
- disease
- lower alkyl
- hydrogen
- benzotiazoles
- legands
- Prior art date
Links
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 title 1
- 229960005305 adenosine Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- -1 2- (7-oxa-bicyclo [2.2.1] hept-1-yl) -ethyl Chemical group 0.000 abstract 2
- 239000001961 anticonvulsive agent Substances 0.000 abstract 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 208000011117 substance-related disease Diseases 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 208000000059 Dyspnea Diseases 0.000 abstract 1
- 206010013975 Dyspnoeas Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 229940025084 amphetamine Drugs 0.000 abstract 1
- 230000003556 anti-epileptic effect Effects 0.000 abstract 1
- 229940125681 anticonvulsant agent Drugs 0.000 abstract 1
- 229960003965 antiepileptics Drugs 0.000 abstract 1
- 239000000164 antipsychotic agent Substances 0.000 abstract 1
- 229940005529 antipsychotics Drugs 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 229930003827 cannabinoid Natural products 0.000 abstract 1
- 239000003557 cannabinoid Substances 0.000 abstract 1
- 229940065144 cannabinoids Drugs 0.000 abstract 1
- 229940045200 cardioprotective agent Drugs 0.000 abstract 1
- 239000012659 cardioprotective agent Substances 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 229960004756 ethanol Drugs 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940035363 muscle relaxants Drugs 0.000 abstract 1
- 239000003158 myorelaxant agent Substances 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 229940005483 opioid analgesics Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229940125723 sedative agent Drugs 0.000 abstract 1
- 239000000932 sedative agent Substances 0.000 abstract 1
- 208000013220 shortness of breath Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
La presente se refiere a los compuestos de la formula general (1), en donde: R1 es cicloalquilo, sustituido por OR o es 2-(7-oxa-biciclo[2.2.1]hept-1-il)-etilo; R es hidrogeno, alquilo inferior o C(O)-alquilo inferior; X es -CHR'-; y R' es hidrogeno o alquilo inferior; y a sales de adicion ácidas farmacéuticamente aceptables, enantiomeros opticamente puros, racematos o mezclas diastereoméricas del mismo para la enfermedad de Alzheimer, enfermedad de Parkinson, enfermedad de Huntington, neuro- proteccion, esquizofrenia, ansiedad, dolor, déficit de respiracion, depresion, ADHD, drogadiccion, tales como de anfetamina, cocaína, opioides, etanol, nicotina, cannabinoides, o para el tratamiento de asma, respuestas alérgicas, hipoxia, isquemia, convulsiones y abuso de sustancias, o para el uso de sedantes, relajantes musculares, antipsicoticos, antiepilépticos, anticonvulsivos y agentes cardioprotectores para la enfermedad de la arteria coronaria y fallo cardíaco.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04103508 | 2004-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049998A1 true AR049998A1 (es) | 2006-09-20 |
Family
ID=35169310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102987A AR049998A1 (es) | 2004-07-22 | 2005-07-20 | BENZOTIAZOLES SUSTITUIDOS COMO LIGANDOS DEL RECEPTOR DE ADENOSINA, PROCESO DE PREPARACIoN Y SU USO |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7449461B2 (es) |
| EP (1) | EP1773795A1 (es) |
| JP (1) | JP2008506735A (es) |
| KR (1) | KR100818028B1 (es) |
| CN (1) | CN1989117B (es) |
| AR (1) | AR049998A1 (es) |
| AU (1) | AU2005263499B2 (es) |
| BR (1) | BRPI0513510A (es) |
| CA (1) | CA2574180A1 (es) |
| MX (1) | MX2007000635A (es) |
| MY (1) | MY140167A (es) |
| RU (1) | RU2381227C2 (es) |
| TW (1) | TW200608970A (es) |
| WO (1) | WO2006008040A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| DE60313216T2 (de) | 2002-12-20 | 2008-01-03 | Niconovum Ab | Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose |
| EP1998748B1 (en) | 2006-03-16 | 2015-01-14 | NicoNovum AB | Improved snuff composition |
| AU2009203773B2 (en) * | 2008-01-11 | 2013-04-18 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
| RU2496496C1 (ru) * | 2012-10-04 | 2013-10-27 | Исаак Григорьевич Гитлин | Фармацевтическая композиция, обладающая гамк-ергической активностью |
| CN115317480B (zh) * | 2022-09-01 | 2023-05-16 | 新乡医学院 | N-(3-甲基-5-异噻唑基)-2-氧代-3-(2h)-苯并噁唑乙酰胺的药物应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL90337A0 (en) * | 1988-05-24 | 1989-12-15 | Pfizer | Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents |
| US6284759B1 (en) * | 1998-09-30 | 2001-09-04 | Neurogen Corporation | 2-piperazinoalkylaminobenzo-azole derivatives: dopamine receptor subtype specific ligands |
| JP3886897B2 (ja) * | 2000-06-21 | 2007-02-28 | エフ．ホフマン−ラ ロシュ アーゲー | ベンゾチアゾール誘導体 |
| US6599901B1 (en) * | 2001-11-19 | 2003-07-29 | Hoffman-La Roche Inc. | Pyridone substituted benzothiazole derivatives |
| US6620811B2 (en) * | 2001-11-19 | 2003-09-16 | Hoffmann-La Roche Inc. | Isonicotin- and nicotinamide derivatives of benzothiazoles |
| JP4216193B2 (ja) * | 2001-11-27 | 2009-01-28 | エフ．ホフマン−ラ ロシュ アーゲー | ベンゾチアゾール誘導体 |
| US6624163B2 (en) * | 2001-11-29 | 2003-09-23 | Hoffman-La Roche Inc. | Benzothiazole derivatives |
| US6727247B2 (en) * | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
| US6713499B2 (en) * | 2001-12-12 | 2004-03-30 | Hoffman-La Roche Inc. | 7-Amino-benzothiazole derivatives |
| KR100765565B1 (ko) * | 2003-05-21 | 2007-10-09 | 에프. 호프만-라 로슈 아게 | 벤조티아졸 유도체 및 그의 아데노신 에이2에이 수용체에관련된 질병의 치료에서의 용도 |
| ATE396726T1 (de) * | 2003-05-30 | 2008-06-15 | Hoffmann La Roche | Benzothiazole derivate und ihre anwendung in der behandlung von adenosine a2a rezeptor vermittelte krankheiten |
-
2005
- 2005-07-13 JP JP2007521856A patent/JP2008506735A/ja not_active Ceased
- 2005-07-13 CA CA002574180A patent/CA2574180A1/en not_active Abandoned
- 2005-07-13 CN CN2005800244293A patent/CN1989117B/zh not_active Expired - Fee Related
- 2005-07-13 WO PCT/EP2005/007591 patent/WO2006008040A1/en not_active Ceased
- 2005-07-13 KR KR1020077001378A patent/KR100818028B1/ko not_active Expired - Fee Related
- 2005-07-13 BR BRPI0513510-9A patent/BRPI0513510A/pt not_active IP Right Cessation
- 2005-07-13 AU AU2005263499A patent/AU2005263499B2/en not_active Expired - Fee Related
- 2005-07-13 MX MX2007000635A patent/MX2007000635A/es active IP Right Grant
- 2005-07-13 EP EP05758611A patent/EP1773795A1/en not_active Withdrawn
- 2005-07-13 RU RU2007101049/04A patent/RU2381227C2/ru not_active IP Right Cessation
- 2005-07-14 US US11/181,573 patent/US7449461B2/en not_active Expired - Fee Related
- 2005-07-20 TW TW094124527A patent/TW200608970A/zh unknown
- 2005-07-20 AR ARP050102987A patent/AR049998A1/es unknown
- 2005-07-20 MY MYPI20053322A patent/MY140167A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0513510A (pt) | 2008-05-06 |
| CN1989117B (zh) | 2011-01-19 |
| MY140167A (en) | 2009-11-30 |
| CA2574180A1 (en) | 2006-01-26 |
| WO2006008040A1 (en) | 2006-01-26 |
| CN1989117A (zh) | 2007-06-27 |
| AU2005263499A1 (en) | 2006-01-26 |
| US7449461B2 (en) | 2008-11-11 |
| US20060019950A1 (en) | 2006-01-26 |
| KR100818028B1 (ko) | 2008-03-31 |
| KR20070027717A (ko) | 2007-03-09 |
| RU2381227C2 (ru) | 2010-02-10 |
| AU2005263499B2 (en) | 2010-11-25 |
| JP2008506735A (ja) | 2008-03-06 |
| MX2007000635A (es) | 2007-03-07 |
| RU2007101049A (ru) | 2008-08-27 |
| TW200608970A (en) | 2006-03-16 |
| EP1773795A1 (en) | 2007-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037528A1 (es) | Derivados de piridona de benzotiazol | |
| DE60309057T2 (de) | Azabicycloderivate als antagonisten des muscarinischen rezeptors | |
| US20170369420A1 (en) | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion | |
| DE10233817A1 (de) | Substituierte Diarylheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel | |
| DE69030963T2 (de) | Liganden für Dopaminerezeptoren und bilderzeugende Mittel | |
| WO2003015769A1 (de) | Aminoalkyl substituierte aromatische bicyclen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| WO1998037061A1 (de) | Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen | |
| SE0104334D0 (sv) | Therapeutic agents | |
| WO2003077869A3 (en) | Neuroprotective spirostenol pharmaceutical compositions | |
| ECSP067018A (es) | (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico | |
| AR049998A1 (es) | BENZOTIAZOLES SUSTITUIDOS COMO LIGANDOS DEL RECEPTOR DE ADENOSINA, PROCESO DE PREPARACIoN Y SU USO | |
| DE102004003811A1 (de) | Substituierte N-Cyclohexylimidazolinone, Verfahren ihrer Herstellung und ihre Verwendung als Arzneimittel | |
| JP2011093855A (ja) | 殺虫性オキサゾリジノン誘導体 | |
| DE69317399T2 (de) | Aminocycloalkanobenzodioxole als beta-3 selektive adrenergische Wirkstoffe | |
| RU2007101052A (ru) | Производные бензотиазола | |
| AR037457A1 (es) | Compuestos derivados de benzotiazol, su empleo, un procedimiento para prepararlos y medicamentos que los contienen | |
| JP2006515611A5 (es) | ||
| DE60216535T2 (de) | Cyclohexylamin-Derivate als N-Methyl-D-Asparat-(NMDA)-Antagonisten | |
| DE60025270T2 (de) | N-substituierte benzyl oder phenyl arylsulfamide und ihre verwendung | |
| DE60102106T2 (de) | Diazacyclooctanverbindungen und ihre therapeutische Verwendung | |
| DE60209698T2 (de) | Mikanolid-derivate, ihre herstellung und ihr gebrauch für therapeutische anwendungen | |
| PE20090517A1 (es) | 2-azetidinametanoaminas y 2-pirrolidinametanoaminas como ligandos de taar | |
| AR063924A1 (es) | Analogos de pirazol | |
| JP2007502848A (ja) | ベンゾチアゾール誘導体、およびアデノシンａ２ａレセプターに関連する疾患の処置におけるその使用 | |
| PT1633355E (pt) | Derivados de benzotiazole e sua utilização no tratamento de doenças relacionadas com os receptores a2a da adenosina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |